Setback for Gilead Hepatitis C Drug
February 21, 2012
Gilead Sciences Inc. on Friday announced that a majority of hepatitis C virus patients in one arm of a clinical trial relapsed after treatment with an experimental drug. Gilead obtained the drug, GS-7977, through its $11 billion purchase of Pharmasset last month. Gilead wants GS-7977 to serve as the anchor for what it hopes will be the first all-oral HCV treatment regimen. The relapses cited involved patients with HCV genotype 1 who previously had little or no response to an interferon-based regimen. The results suggest additional antiviral drugs may be needed, which Gilead said it will be exploring. GS-7977 has shown positive results with other HCV genotypes, including genotypes 2 and 3. Further trial results, including for treatment-naive HCV genotype 1 patients, will be released in the coming months.
Wall Street Journal
02.17.2012; Peter Loftus
Results From Investigational Studies With Victrelis (Boceprevir) Presented at CROI to Understand Potential Use in Patients Coinfected With Chronic Hepatitis C and HIV-1
This article was provided by CDC National Prevention Information Network. It is a part of the publication CDC HIV/Hepatitis/STD/TB Prevention News Update.
Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy.)